LifeSci Acquisition – a so-called ‘blank cheque’ company – has announced a $60 million merger with Vincera Pharma that will focus on developing cancer drugs.
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio